- Conditions: Full Iris Defects; Partial Iris Defects
Intervention: Device: Artificial Iris (CustomFlex)
Sponsors: HumanOptics AG; HumanOptics AG
Not yet recruiting - verified May 2013 - Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab (REGN668/ SAR231893); Drug: Placebo
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013 - Condition: Hodgkin Disease
Interventions: Drug: ABVE-PC in Rapid Early Responders; Drug: DECA in Slow Early Responders
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: LEE011; Drug: Exemestane; Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013 - Condition: Advanced Cancers
Interventions: Drug: Fentanyl Buccal Tablet; Other: Placebo Buccal Tablet; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Teva Pharmaceuticals USA
Not yet recruiting - verified May 2013 - Condition: Congestive Heart Failure
Interventions: Drug: D-ribose; Other: Placebo
Sponsors: RiboCor, Inc.; RiboCor, Inc.
Not yet recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013 - Condition: Brain Cancer
Interventions: Radiation: IMPT; Radiation: IMRT; Behavioral: Cognitive Tests; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013 - Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease
Interventions: Biological: Infusion of one MPC expanded cord unit and one unexpanded cord unit; Biological: Infusion of two unexpanded cord blood units.
Sponsors: Mesoblast, Ltd.; Mesoblast, Ltd.
Recruiting - verified May 2013 - Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: docosahexaenoic acid; Other: placebo; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Astigmatism
Interventions: Device: Etafilcon A; Device: Etafilcon A Astigmatism
Sponsors: Vistakon; Vistakon
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention: Biological: autologous bone marrow mononuclear cells
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified May 2013 - Conditions: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia
Intervention: Biological: CD19 Specific CAR T Cells
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Not yet recruiting - verified May 2013 - Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Opioid-Related Disorders,; Opiate Dependence
Interventions: Drug: OX219 buprenorphine/naloxone; Drug: Buprenorphine
Sponsors: Orexo AB; Orexo AB; Worldwide Clinical Trials
Not yet recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: MPDL3280A
Sponsors: Genentech; Genentech
Not yet recruiting - verified May 2013 - Condition: Head and Neck Cancer
Interventions: Behavioral: Questionnaires; Other: Quantitative Sensory Testing
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified May 2013 - Conditions: Obesity; Type 2 Diabetes
Intervention: Behavioral: 1)Diab and 2)Nanoswarm
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Not yet recruiting - verified May 2013 - Condition: Head And Neck Cancer
Interventions: Other: Swallowing Exercises; Behavioral: Symptom Inventory; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified May 2013 - Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo; Drug: Rifaximin
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013 - Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified April 2013 - Condition: Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions: Drug: Tremelimumab; Drug: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2013 - Condition: Coronary Artery Bypass Grafting
Intervention: Procedure: Vein Harvesting Procedures
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified May 2013 - Conditions: End-stage Renal Disease; Kidney Failure, Chronic
Intervention: Biological: HAVG
Sponsors: Humacyte, Inc.; Humacyte, Inc.; FGK Clinical Research GmbH; Aptiv Solutions US
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention: Drug: Reparixin
Sponsors: Dompé s.p.a.; Dompé s.p.a.
Recruiting - verified May 2013 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: QVA149; Drug: fluticasone/salmeterol
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013 - Condition: Advanced Cancers
Interventions: Drug: Fentanyl Pectin Nasal Spray; Drug: Placebo Nasal Spray; Other: Walk Test; Behavioral: Questionnaires; Behavioral: Mental Ability Tests
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archimedes Development Ltd
Not yet recruiting - verified May 2013 - Condition: Leukemia, Hairy Cell
Interventions: Drug: moxetumomab pasudotox; Drug: IV Bag Protectant for Moxetumomab pasudtox
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013 - Condition: Myelodysplastic Syndrome
Interventions: Drug: TL32711; Drug: 5-Azacitidine
Sponsors: TetraLogic Pharmaceuticals; TetraLogic Pharmaceuticals
Not yet recruiting - verified April 2013 - Condition: Melanoma
Interventions: Drug: ABI-007; Drug: Ipilimumab; Behavioral: Phone Call
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified April 2013 - Condition: Smallpox
Intervention: Biological: IMVAMUNE®
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2013 - Condition: Hypertension, Pulmonary
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013 - A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed DyslipidemiaCondition: Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention: Device: AMG 145
Sponsors: Amgen; Amgen
Not yet recruiting - verified May 2013 - Condition: Leukemia
Interventions: Drug: Busulfan; Drug: Fludarabine; Procedure: Alloreactive NK infusion; Drug: Interleukin-2; Drug: Thymoglobulin; Procedure: Stem Cell Infusion; Drug: G-CSF; Drug: Tacrolimus; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CPRIT Grant; CML Program Project Grant
Not yet recruiting - verified May 2013 - Conditions: HIV; HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Muscular Dystrophy, Duchenne; Muscular Dystrophies; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn
Interventions: Drug: Ataluren; Drug: Placebo
Sponsors: PTC Therapeutics; PTC Therapeutics
Recruiting - verified April 2013 - Condition: Esophageal Squamous Cell Carcinoma
Interventions: Drug: LJM716; Drug: BYL719; Drug: Paclitaxel; Drug: Docetaxel; Drug: Irinotecan
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013 - Condition: Colorectal Carcinoma
Intervention: Drug: Metformin ER
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013 - Condition: Infertility
Interventions: Drug: Placebo; Drug: Dexamethasone
Sponsors: San Antonio Military Medical Center; San Antonio Military Medical Center
Not yet recruiting - verified May 2013 - Condition: Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo to MK-3102; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions: Drug: LCQ908; Drug: placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2013 - Conditions: Insular Thyroid Cancer; Recurrent Thyroid Cancer; Stage I Follicular Thyroid Cancer; Stage I Papillary Thyroid Cancer; Stage II Follicular Thyroid Cancer; Stage II Papillary Thyroid Cancer; Stage III Follicular Thyroid Cancer; Stage III Papillary Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cabozantinib-s-malate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: Autism
Intervention:
Sponsors: SynapDx; SynapDx
Recruiting - verified May 2013 - Condition: Myeloma
Interventions: Drug: Pomalidomide; Drug: Melphalan; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Tufts Medical Center
Not yet recruiting - verified May 2013 - Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Not yet recruiting - verified May 2013 - Condition: Lymphoma
Intervention: Drug: CD5789 0.01% Cream
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Galderma R&D
Recruiting - verified April 2013 - Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Posterolateral Thoracotomy; Postoperative Pain
Interventions: Drug: Liposome bupivacaine; Drug: Placebo
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Endometrial Cancer
Interventions: Drug: Metformin; Drug: Letrozole; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis; SPORE Grant
Not yet recruiting - verified May 2013 - Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013 - Conditions: Infant, Newborn; Infant, Moderate Preterm
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified February 2013 - Condition: Myeloma
Interventions: Drug: Minocycline; Other: Placebo; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Prostate Cancer
Interventions: Drug: Lupron; Drug: Zoladex; Drug: Degarelix; Drug: Abiraterone Acetate; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Janssen Services, LLC
Recruiting - verified May 2013 - Conditions: Burkitt Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: SGN-CD19A
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Intervention: Drug: Riociguat (BAY 63-2521)
Sponsors: Bayer; Bayer
Available - verified April 2013 - Conditions: Gastrointestinal; Colic
Intervention: Biological: Lactobacillus reuteri
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Not yet recruiting - verified May 2013 - Condition: Kidney Transplantation
Interventions: Drug: ASKP1240; Drug: Tacrolimus; Drug: Mycophenolate Mofetil (MMF); Drug: Basiliximab; Drug: Corticosteroids
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.; Kyowa Hakko Kirin Company, Limited
Recruiting - verified April 2013 - Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013 - Conditions: HIV; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Drug: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Kidney Cancer
Intervention: Drug: Carfilzomib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Onyx Therapeutics, Inc.
Not yet recruiting - verified May 2013 - Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Venous Thromboembolism
Intervention: Drug: dabigatran etexilate
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; National Surgical Adjuvant Breast and Bowel Project (NSABP); German Breast Group
Recruiting - verified May 2013 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Conditions: Amnestic Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: Insulin (Humulin® R U-100); Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified May 2013 - Condition: Eyebrow Hypotrichosis
Interventions: Drug: bimatoprost solution; Drug: Vehicle to bimatoprost solution
Sponsors: Allergan; Allergan
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659; Drug: PF-00547659
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Placebo (administered subcutaneously); Drug: Ezetimibe; Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Metastatic or Unresectable Cutaneous Melanoma
Interventions: Drug: MEK162; Drug: Dacarbazine
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013 - Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin; Drug: Moxifloxacin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Tivantinib; Drug: Placebo
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; ArQule; Covance
Recruiting - verified April 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3012; Drug: Matching placebo to MK-3012; Drug: Glimepiride; Drug: Matching placebo to glimepiride; Drug: Insulin glargine; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Prosthetic Joint Infections of Hip or Knee Joints
Interventions: Drug: CEM-102 plus Rifampin; Drug: IV vancomycin, nafcillin, oxacillin, ceftriaxone or cefazolin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Burkitt Lymphoma; Burkitt Leukemia; Diffuse Large B Cell Lymphoma; Post Transplant Lymphoproliferative Disorder; Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions: Drug: DA-EPOCH-R for BL and B-ALL; Drug: Methotrexate; Drug: Etoposide; Drug: Doxorubicin; Drug: Vincristine; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Prednisone; Drug: G-CSF; Drug: DA-EPOCH-R for DLBCL, PTLD & PMBCL
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH); Texas Children's Hospital
Recruiting - verified May 2013 - Conditions: Inflammation; Crohn's Disease
Interventions: Drug: NNC0114-0006; Drug: NNC0114-0006
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Advanced Cancers
Interventions: Drug: Ipilimumab; Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Dry Eye
Interventions: Drug: Lifitegrast; Drug: Placebo
Sponsors: SARcode Bioscience; SARcode Bioscience
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Vancomycin inhalation powder; Drug: Placebo inhalation powder
Sponsors: Savara Inc.; Savara Inc.; Synteract, Inc.
Recruiting - verified May 2013 - Condition: Leukemia Lymphocytic Chronic B-Cell
Interventions: Drug: CC-292; Drug: Rituximab
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Conditions: Multiple Myeloma; Lymphoma
Intervention: Drug: CUDC-907
Sponsors: Curis, Inc.; Curis, Inc.; The Leukemia and Lymphoma Society
Recruiting - verified April 2013 - Condition: Eisenmenger Syndrome
Interventions: Drug: Macitentan 10 mg, oral tablet, to be taken once daily.; Drug: Matching placebo oral tablet, to be taken once daily.
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Condition: Eisenmenger Syndrome
Intervention: Drug: Macitentan 10 mg tablet, once daily.
Sponsors: Actelion; Actelion
Not yet recruiting - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Conditions: Anemia; Myelodysplastic Syndromes (MDS); Chronic Myelomonocytic Leukemia (CMML); Low to Intermediate-1 MDS
Interventions: Drug: Sotatercept 0.1 mg/kg; Drug: Sotatercept 0.3 mg/kg; Drug: Sotatercept 0.5 mg/kg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Condition: Tardive Dyskinesia
Interventions: Drug: NBI-98854; Drug: NBI-98854; Drug: Placebo
Sponsors: Neurocrine Biosciences; Neurocrine Biosciences
Recruiting - verified May 2013 - Conditions: Iron Deficiency; Iron Deficiency Anemia
Intervention: Drug: Ferric Citrate
Sponsors: Keryx Biopharmaceuticals; Keryx Biopharmaceuticals
Recruiting - verified May 2013 - Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: BI 201335 (Faldaprevir); Drug: BI 201335 (Faldaprevir); Drug: BI 207127; Drug: BI 207127; Drug: Faldaprevir (BI 201335)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: Melphalan; Procedure: NK Cell Infusion; Drug: Interleukin-2; Procedure: Stem Cell Infusion; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Not yet recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Conditions: Cord Blood Stem Cell Transplantation; Cord Blood Transplantation; Hematopoietic Stem Cell Transplantation
Intervention:
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Lymphoma
Interventions: Drug: Carfilzomib; Drug: Lenalidomide; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Onyx Therapeutics, Inc.
Recruiting - verified April 2013 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: tivantinib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001 (sodium nitrite inhalation solution)
Sponsors: Aires Pharmaceuticals, Inc.; Aires Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001
Sponsors: Aires Pharmaceuticals, Inc.; Aires Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Conditions: Diabetes Mellitus, Type 2; Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose qd; Drug: Empagliflozin low dose bid; Drug: Metformin 500 mg bid; Drug: Empagliflozin high dose bid; Drug: Empagliflozin low dose bid; Drug: Metformin 1000 mg bid; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Drug: Plecanatide; Drug: Placebo
Sponsors: Synergy Pharmaceuticals, Inc.; Synergy Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013 - Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Leigh Syndrome
Interventions: Drug: Placebo; Drug: EPI-743 15 mg/kg; Drug: EPI-743 5 mg/kg
Sponsors: Edison Pharmaceuticals Inc; Edison Pharmaceuticals Inc; Axio Research. LLC; Biosoteria
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: PCI-32765; Drug: Chlorambucil
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified May 2013 - Condition: To Determine the Psychometric Properties of the Short Child Occupational Profile (SCOPE) and Validate the SCOPE.
Intervention:
Sponsors: Texas Woman's University; Texas Woman's University
Recruiting - verified May 2013 - Conditions: Colorectal Cancer; Cancer of Gastrointestinal Tract
Intervention: Drug: Abraxane
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified May 2013 - Condition: Influenza
Interventions: Drug: oseltamivir [Tamiflu]; Drug: oseltamivir [Tamiflu]; Drug: oseltamivir [Tamiflu]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/insulin aspart; Drug: insulin degludec; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: sarilumab SAR153191 (REGN88); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Diabetic Nephropathy
Interventions: Drug: PF-04634817; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Adalimumab; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Plaque Psoriasis
Interventions: Drug: (CP-6890,550) Tofacitinib; Drug: Placebo; Drug: (CP-690,550) Tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Cervical Cancer
Interventions: Device: Intracavitary Applicator Placement; Other: Computed Tomography (CT); Other: Magnetic Resonance Imaging (MRI)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Cystic Fibrosis
Intervention: Drug: ivacaftor
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo to MK-3102; Drug: Glipizide; Drug: Placebo to glipizide; Biological: Insulin
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).; Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.; Biological: Varivax® (Merck & Co., Inc.); Biological: Havrix®; Biological: Prevnar 13® (Pfizer Inc.)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Neuropathic Pain
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Condition: Gynecology
Interventions: Drug: Metformin; Other: Placebo; Procedure: Endometrial Biopsy; Behavioral: Lifestyle Intervention; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; SPORE
Recruiting - verified May 2013 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013 - Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351; Drug: 7+3 (cytarabine and daunorubicin)
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals; The Leukemia and Lymphoma Society
Recruiting - verified May 2013 - Condition: Malignant Melanoma
Intervention: Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified May 2013 - Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Premature Infants
Intervention: Dietary Supplement: Vitamin D
Sponsors: Baylor College of Medicine; Baylor College of Medicine; USDA Beltsville Human Nutrition Research Center; Mead Johnson Nutrition
Recruiting - verified May 2013 - Condition: Pancreatic Cancer
Interventions: Drug: Minocycline; Other: Placebo; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Leukemia
Interventions: Drug: E7070; Drug: Idarubicin; Drug: Cytarabine; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Recruiting - verified May 2013 - Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified May 2013 - Condition: Cocaine Dependence
Interventions: Drug: Nepicastat; Drug: Placebo
Sponsors: National Institute on Drug Abuse (NIDA); National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2013 - Conditions: Inflammation; Systemic Lupus Erythematosus
Interventions: Drug: NNC0114-0006; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013 - Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: Ribavirin
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Venous Thrombosis
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Other: Standard of care
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin/Simvastatin FDC; Drug: Sitagliptin; Drug: Simvastatin; Drug: Placebo to sitagliptin; Drug: Placebo to simvastatin; Drug: Placebo to Sitagliptin/Simvastatin FDC; Drug: Metformin; Drug: Glimepiride
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Postoperative Pain
Interventions: Drug: EXPAREL; Drug: Placebo
Sponsors: Pacira Pharmaceuticals, Inc; Pacira Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Diabetic Kidney Disease
Interventions: Drug: baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified May 2013 - Condition: Narcolepsy
Interventions: Drug: ADX-N05; Drug: Placebo
Sponsors: Aerial BioPharma, LLC; Aerial BioPharma, LLC
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: MOR00208 (formerly Xmab5574)
Sponsors: MorphoSys AG; MorphoSys AG
Recruiting - verified April 2013 - Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide; Drug: liraglutide; Drug: exenatide
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg); Drug: Placebo tablets
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013 - Condition: Paroxysmal Atrial Fibrillation (PAF)
Interventions: Device: Blazer Open-Irrigated Ablation Catheter (Boston Scientific); Device: FDA Approved Open-Irrigated Ablation Catheter
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified May 2013 - Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Vitamin K antagonist (VKA)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Condition: Central Nervous System Neoplasms
Interventions: Behavioral: Three-Factor Eating Questionnaire (TFEQ)-R18v2; Behavioral: Multifactor Screener; Behavioral: Eating Questionnaire-EMA (EQ-EMA)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Baylor College of Medicine; Texas Children's Cancer Center
Recruiting - verified May 2013 - Condition: Ischemic Dilated Cardiomyopathy (IDCM)
Interventions: Biological: ixmyelocel-T; Other: Vehicle Control
Sponsors: Aastrom Biosciences; Aastrom Biosciences
Recruiting - verified May 2013 - Conditions: Advanced Cancers; Hematologic Disorder; Solid Tumors
Interventions: Drug: Dexamethasone; Drug: Placebo; Behavioral: Questionnaires; Device: Spirometer; Other: Phone Calls
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Everolimus
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: BI 695500; Drug: BI 695500; Drug: rituximab; Drug: rituximab; Drug: rituximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Leukemia
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Astellas Pharma Inc
Recruiting - verified May 2013 - Condition: Schizophrenia
Intervention: Drug: Aripiprazole IM Depot
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.; H. Lundbeck A/S; Otsuka America Pharmaceutical
Recruiting - verified May 2013 - Condition: Anal Cancer
Intervention: Biological: Advaxis
Sponsors: Brown University; Brown University; Rhode Island Hospital; The Miriam Hospital; Montefiore Medical Center; M.D. Anderson Cancer Center; Boston Medical Center; Ohio State University Comprehensive Cancer Center; University of Pennsylvania
Recruiting - verified May 2013 - Condition: Infusion Reactions
Intervention: Drug: unlicensed cord blood units
Sponsors: New York Blood Center; New York Blood Center
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: empagliflozin (low dose qd); Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Empagliflozin (high dose qd); Drug: empagliflozin (high dose bid); Drug: Placebo; Drug: empagliflozin (low dose bid)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Advanced Cancers; Leukemia
Interventions: Procedure: Leukapheresis; Drug: Fludarabine; Drug: Cyclophosphamide; Procedure: T-cell Infusion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2013 - Condition: Thyroid Cancer
Interventions: Drug: Vemurafenib (All Groups); Drug: Vemurafenib (Post Surgery) - Group A + C; Other: Post Surgery - Group B
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: belimumab 10mg/kg; Other: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company
Recruiting - verified April 2013 - Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Conditions: Cervical Cancer; Lymphedema; Sexuality and Reproductive Issues
Interventions: Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cone biopsy; Procedure: genitourinary surgical procedure; Procedure: loop electrosurgical excision procedure; Procedure: quality-of-life assessment; Procedure: therapeutic laparoscopic surgery; Procedure: therapeutic lymphadenectomy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727); Drug: matching placebo SAR236553 (REGN727); Drug: Ezetimibe; Drug: matching placebo for Ezetimibe
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013 - Condition: Ankylosing Spondylitis
Interventions: Biological: AIN457; Biological: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Pneumococcal Infections
Intervention: Biological: Prevnar 13 (PVC13)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2013 - Condition: Gastric Cancer
Interventions: Drug: trastuzumab emtansine; Drug: trastuzumab emtansine; Drug: taxane
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: 20 mg/kg TRU-016 + Rituximab; Biological: 10 mg/kg TRU-016 + Rituximab
Sponsors: Emergent Product Development Seattle LLC; Emergent Product Development Seattle LLC
Recruiting - verified April 2013 - Conditions: Pulmonary Arterial Hypertension; Congenital Heart Disease
Intervention: Other: observational
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013 - Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Conditions: Breast Cancer; HER-2 Positive Breast Cancer; Triple Negative Breast Cancer
Intervention: Drug: ganetespib
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: MK-1029 10 mg; Drug: MK-1029 30 mg; Drug: MK-1029 150 mg; Drug: Montelukast 10 mg; Drug: Placebo; Drug: MK-1029 1 mg or 3 mg; Drug: Montelukast 10 mg + MK-1029
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Condition: Leukemia
Interventions: Drug: Cytarabine; Drug: 5-Azacytidine; Drug: Tosedostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Cell Therapeutics
Recruiting - verified May 2013 - Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Chronic Renal Failure Requiring Hemodialysis
Intervention: Biological: Epoetin Hospira
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013 - Condition: Polycythemia Vera
Interventions: Drug: ruxolitinib and HU-placebo; Drug: HU and ruxolitinib-placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Condition: Metastatic Breast Cancer HR+, HER2-
Interventions: Drug: Fulvestrant; Drug: BKM120; Drug: BKM120 matching placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Perennial Allergic Rhinitis (PAR)
Intervention: Drug: Beclomethasone Dipropionate (BDP) Nasal Aerosol
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; United BioSource Corporation
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: MK-1439; Drug: Efavirenz; Drug: TRUVADA®
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: RO5466731; Drug: RO5190591; Drug: ritonavir; Drug: ribavirin [Copegus]; Drug: RO5024048
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Prostate Cancer
Interventions: Drug: Cabozantinib; Drug: Androgen Ablation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Exelixis
Not yet recruiting - verified May 2013 - Conditions: Primary Myelofibrosis; Post Polycythemia Vera Fibrosis; Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: INCB039110
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Condition: Asthma
Intervention: Device: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Sponsors: American Lung Association Asthma Clinical Research Centers; American Lung Association Asthma Clinical Research Centers; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Condition: Parkinson's Disease
Intervention:
Sponsors: National Parkinson Foundation; National Parkinson Foundation
Recruiting - verified May 2013 - Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Intervention: Drug: asparaginase Erwinia chrysanthemi
Sponsors: EUSA Pharma (US), Inc.; EUSA Pharma (US), Inc.
Recruiting - verified May 2013 - Conditions: HIV Infection; Pregnancy
Intervention: Other: questionaires and structured interviews
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Advanced Cancers
Interventions: Device: Litebook; Drug: Melatonin; Drug: Methylphenidate; Drug: Placebo; Behavioral: Counseling Sessions; Behavioral: Questionnaires; Behavioral: Study Diaries
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified April 2013 - Condition: Head and Neck Cancer
Interventions: Other: Chart Review; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Epilepsy
Intervention: Device: Cyberonics Investigational Accelerometry Device & Cyberonics Investigational Weighted Simulant Device
Sponsors: Cyberonics, Inc.; Cyberonics, Inc.
Recruiting - verified April 2013 - Condition: Narcolepsy
Intervention: Drug: Armodafinil
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013 - Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®; Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™); Biological: Kinrix®; Biological: Varivax®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Conditions: Advanced Melanoma; Metastatic Melanoma
Intervention: Biological: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013 - Conditions: Type 2 Diabetes; Chronic Kidney Disease
Interventions: Drug: Dulaglutide; Drug: Insulin glargine; Drug: Insulin lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection; Drug: PF-00547659 SC Injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Leukemia; Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Fludarabine monophosphate; Drug: Melphalan; Procedure: NK Infusion; Procedure: CB Infusion; Drug: Tacrolimus; Drug: Mycophenolate mofetil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Neoplasms; Tumor
Intervention: Biological: IMC-TR1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2013 - Condition: Cancer
Intervention: Biological: WT2725
Sponsors: Sunovion; Sunovion; Dainippon Sumitomo Pharma
Recruiting - verified April 2013 - Condition: Cystic Fibrosis
Interventions: Drug: Ivacaftor; Drug: Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation
Recruiting - verified April 2013 - Conditions: Congestive Heart Failure; Left Ventricular (LV) Systolic Dysfunction
Intervention: Device: CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)
Sponsors: CardioKinetix, Inc; CardioKinetix, Inc
Recruiting - verified May 2013 - Condition: Emphysema
Intervention: Device: PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Sponsors: PneumRx, Inc.; PneumRx, Inc.
Recruiting - verified December 2012 - Condition: Stomach Neoplasms; Esophageal Neoplasms; Metastatic Gastric Cancer; Mutated PI3KCA Protein; Overexpressed HER2 Protein;
Interventions: Drug: AUY922; Drug: BYL719
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Coronary Artery Disease (CAD)
Intervention: Drug: Regadenoson
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Acute Kidney Injury
Interventions: Biological: AC607; Biological: Vehicle Only
Sponsors: AlloCure Inc.; AlloCure Inc.
Recruiting - verified May 2013 - Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: End-stage Renal Disease
Interventions: Device: Heparin-bonded vascular access graft; Device: Conventional ePTFE hemodialysis graft
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified May 2013 - Condition: Diabetic Nephropathy
Interventions: Drug: Repository Corticotropin Injection; Drug: Placebo
Sponsors: Questcor Pharmaceuticals, Inc.; Questcor Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Behavioral: Questionnaires; Other: Education Materials; Other: Luvena; Other: Hyalo-Gyn; Other: Vaginal Lubricant; Behavioral: Interactive Internet-Based Website; Behavioral: Telephone Counseling.
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Fidia Farmaceutici s.p.a.; Laclede Inc. Healthcare Products
Recruiting - verified May 2013 - Condition: Solid Pancreatic Mass Lesions
Intervention: Device: Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Eisenmenger
Intervention: Other: Management
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: PBO; Drug: 200mg PF-04950615 (RN316); Drug: 300mg PF-04950615 (RN316); Drug: PBO; Drug: PF-04950615; Drug: PF-04950615; Drug: PF-04950615
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma; HER2 + Breast Cancer; HER2 + Gastric Cancer; Squamous Cell Carcinoma of Head and Neck; Esophageal Squamous Cell Carcinoma
Intervention: Drug: LJM716
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Brain Neoplasms
Interventions: Radiation: Stereotactic Radiosurgery (SRS); Radiation: Whole Brain Radiation Therapy (WBRT); Behavioral: Questionnaires; Behavioral: Cognitive Function Tests
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Advanced Cancers
Intervention: Drug: siRNA-EphA2-DOPC
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ovarian Cancer Research Fund
Not yet recruiting - verified May 2013 - Condition: Proliferative Diabetic Retinopathy
Interventions: Drug: Macugen; Drug: Sham
Sponsors: Greater Houston Retina Research; Greater Houston Retina Research
Recruiting - verified May 2013 - Condition: Clostridium Difficile-associated Diarrhea
Intervention: Drug: fidaxomicin
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified April 2013 - Conditions: Adenocarcinoma of the Pancreas; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: veliparib; Drug: gemcitabine hydrochloride; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant dimeglumine; Drug: Fosaprepitant Placebo; Drug: Dexamethasone; Drug: Ondansetron; Drug: Dexamethasone Placebo; Drug: Ondansetron Placebo; Drug: Rescue Therapy
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Severe Aortic Stenosis
Interventions: Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Procedure: Surgical Aortic Valve Replacement (SAVR)
Sponsors: Medtronic Cardiovascular; Medtronic Cardiovascular
Recruiting - verified May 2013 - Condition: Anaemia
Interventions: Drug: GSK1278863; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline; PPD
Recruiting - verified April 2013 - Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2013 - Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified May 2013 - Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: TPI287; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Advanced Cancers
Interventions: Drug: Vandetanib; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Type 2 Diabetes
Interventions: Drug: Mesenchymal Precursor Cells (MPCs); Drug: Mesenchymal Precursor Cells (MPCs); Drug: Mesenchymal Precursor Cells (MPCs)
Sponsors: Mesoblast, Ltd.; Mesoblast, Ltd.
Recruiting - verified April 2013 - Condition: Traumatic Brain Injury
Intervention: Biological: autologous bone marrow mononuclear cells
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified May 2013 - Condition: Huntington's Disease
Intervention:
Sponsors: CHDI Foundation, Inc.; CHDI Foundation, Inc.
Recruiting - verified May 2013 - Conditions: Leukemia; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Diseases; Non-Hodgkins Lymphoma; Hodgkins Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome
Interventions: Drug: Fludarabine monophosphate; Drug: Busulfan; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone; Drug: Velcade plus dexamethasone
Sponsors: Onyx Pharmaceuticals; Onyx Pharmaceuticals
Recruiting - verified May 2013 - Condition: Viral Infection
Intervention: Biological: Multi-virus-specific cytotoxic T lymphocytes
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2013 - Condition: CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions: Drug: Part 1, Cohort 1; Drug: Part 1, Cohort 2; Drug: Part 1, Cohort 3; Drug: Part 2, Cohort 1; Drug: Part 2, Cohort 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: STF 115469 Foam; Drug: Vehicle Foam
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Right Ventricular Failure
Intervention: Device: CentriMag RVAS placement
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013 - Condition: Hemophilia A
Intervention: Biological: BAY94-9027
Sponsors: Bayer; Bayer
Recruiting - verified April 2013 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Condition: Pre-eclampsia
Interventions: Drug: Placebo; Drug: RLX030
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: inotuzumab ozogamicin; Drug: FLAG (fludarabine, cytarabine and G-CSF); Drug: HIDAC (high dose cytarabine); Drug: cytarabine and mitoxantrone
Sponsors: Pfizer; Pfizer; Union Chimique Belge
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: vinorelbine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Pancreatic Cancer
Interventions: Drug: Oxaliplatin; Drug: Irinotecan; Drug: 5-FU; Drug: Gemcitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Psoriasis
Intervention: Drug: calcipotriene
Sponsors: GlaxoSmithKline; Stiefel, a GSK Company; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Myocardial Ischemia
Interventions: Device: ADRCs processed by the Celution System; Device: Placebo Comparator: Lactated Ringer's and Subject's Blood
Sponsors: Cytori Therapeutics; Cytori Therapeutics
Recruiting - verified April 2013 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Major Depressive Disorder, Recurrent
Interventions: Drug: MK-6096; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Parkinson's Disease; Primary Parkinsonism; Lewy Body Parkinson's Disease
Intervention: Drug: 18F-AV-133
Sponsors: Avid Radiopharmaceuticals; Avid Radiopharmaceuticals
Recruiting - verified May 2013 - Condition: Advanced Cancers
Interventions: Drug: Crizotinib (Xalkori); Drug: Pazopanib; Drug: Pemetrexed
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer
Interventions: Drug: CC-223; Drug: Erlotinib; Drug: Oral azacitidine concurrent; Drug: oral azacitidine sequential
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013 - Conditions: Trisomy 13; Trisomy 18; Trisomy 21; Aneuploidy
Intervention: Procedure: Blood Draw
Sponsors: Natera, Inc.; Natera, Inc.; Columbia University; George Washington University; National Institutes of Health (NIH)
Recruiting - verified May 2013 - Conditions: Chronic Inflammatory Demyelinating Polyneuropathy; Polyradiculoneuropathy
Interventions: Biological: IgPro20; Biological: Placebo
Sponsors: CSL Behring; CSL Behring; Parexel
Recruiting - verified May 2013 - Condition: Acute Myeloid Leukemia
Interventions: Drug: PF-04449913; Drug: Low dose ARA-C (LDAC); Drug: PF-04449913; Drug: Decitabine; Drug: PF-04449913; Drug: Daunorubicin; Drug: Cytarabine; Drug: Pf-04449913; Drug: Daunorubicin; Drug: Cytarabine; Drug: PF-04449913; Drug: Low dose ARA-C (LDAC)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Magnetic Resonance Imaging
Intervention: Drug: Gadobutrol (Gadavist, BAY86-4875)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Schizophrenia
Interventions: Drug: AMG 747; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Condition: Advanced Parkinson's Disease
Interventions: Drug: Rotigotine; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013 - Conditions: Advanced Cancers; DLBCL; Lymphoma
Intervention: Drug: ISIS-STAT3Rx
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals; AstraZeneca
Recruiting - verified April 2013 - Condition: Sclerosis, Systemic
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: Placebo; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Advanced Cancers
Interventions: Drug: Vemurafenib; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Multiple Myeloma, Neoplasms
Intervention: Drug: Vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013 - Conditions: Leukemia; Lymphoma; Myeloma; Myeloproliferative Diseases
Interventions: Drug: Fludarabine; Drug: Melphalan; Drug: Alemtuzumab; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF; Procedure: Low Dose Donor T-Cells; Procedure: High Dose Donor T-Cells
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Conditions: Metastatic Castration-resistant Prostate Cancer; Metastatic Breast Cancer
Interventions: Drug: Abiraterone acetate; Drug: Abiraterone acetate
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Kidney Transplant
Interventions: Drug: Tacrolimus + MMF + Prednisone, followed by Tacrolimus Withdrawal; Drug: MMF/Tacrolimus/Prednisone
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified May 2013 - Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Malignant Melanoma
Intervention: Drug: vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Chronic Myocardial Ischemia; Refractory Angina Pectoris; (Advanced) Coronary Heart Disease
Interventions: Biological: Auto-CD34+ cells; Biological: Placebo: Diluent used to suspend Auto-CD34+ cells; Other: Standard of care
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2013 - Condition: Liver Cancer
Interventions: Drug: RO5137382; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Psychosocial Problem
Interventions: Behavioral: Health Education; Behavioral: Questionnaires; Behavioral: Telephone Counseling Sessions; Drug: Nicotine Patches
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified May 2013 - Condition: Uterine Fibroids
Interventions: Device: MR-HIFU treatment; Device: Sham treatment
Sponsors: Philips Healthcare; Philips Healthcare
Recruiting - verified May 2013 - Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified May 2013 - Condition: Hemophilia B
Intervention: Biological: rIX-FP
Sponsors: CSL Behring; CSL Behring
Recruiting - verified May 2013 - Conditions: Leukemia; Lymphoma
Interventions: Procedure: HSCT; Genetic: DLI
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Complicated Intra-Abdominal Infection
Interventions: Drug: CAZ-AVI; Drug: Metronidazole; Drug: Meropenem
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Recruiting - verified May 2013 - Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013 - Condition: Colorectal Neoplasms
Interventions: Behavioral: CRCS patient decision aid (PtDA) video; Behavioral: Questionnaires; Behavioral: Essential Hypertension video
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Leukemia; Lymphoma
Interventions: Drug: Rituximab; Drug: 111In Ibritumomab; Procedure: Planar Scintigraphy Imaging; Drug: 90Y IbritumomabTiuxetan; Drug: Fludarabine; Drug: Bendamustine; Drug: Thymoglobulin; Drug: Tacrolimus; Drug: Methotrexate; Drug: Mycophenolate; Drug: G-CSF; Procedure: Stem Cell Transplantation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013 - Condition: Iron Absorption
Intervention:
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified May 2013 - Condition: Cervical Dystonia
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified April 2013 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Hepatitis B, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Ovarian Cancer Recurrent
Interventions: Drug: EP-100; Drug: Paclitaxel
Sponsors: Esperance Pharmaceuticals Inc; Esperance Pharmaceuticals Inc
Recruiting - verified May 2013 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2013 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013 - Condition: Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac; Drug: Eflornithine and Placebo; Drug: Sulindac and Placebo
Sponsors: Cancer Prevention Pharmaceuticals, Inc.; Cancer Prevention Pharmaceuticals, Inc.
Not yet recruiting - verified May 2013 - Condition: Obesity
Intervention: Behavioral: Food, Fun, & Fitness Internet Program for Girls
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Center on Minority Health and Health Disparities (NCMHD)
Recruiting - verified April 2013 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Hemophilia A
Intervention: Biological: Recombinant Factor VIII (rFVIII)
Sponsors: CSL Behring; CSL Behring
Recruiting - verified May 2013 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Metformin; Drug: Sitagliptin / Metformin; Drug: Placebo to Metformin; Drug: Placebo to Sitagliptin / Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Chronic Kidney Disease; Chronic Renal Failure
Interventions: Biological: Epoetin Hospira; Biological: Epogen (Amgen)
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013 - Condition: Lymphoma
Interventions: Drug: Rituximab; Radiation: Radiation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Brain Cancer
Intervention: Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Ischemic Stroke
Interventions: Drug: Argatroban; Drug: Argatroban
Sponsors: The University of Texas Health Science Center, Houston; Andrew Barreto; The University of Texas Health Science Center, Houston
Recruiting - verified May 2013 - Conditions: Chronic Renal Failure; Chronic Kidney Disease
Interventions: Biological: Epoetin Hospira; Biological: Epogen Amgen
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013 - Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: tofacitinib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Intracranial Aneurysms; Peripheral Aneurysms
Intervention: Device: PC 400 coils (Penumbra )
Sponsors: Penumbra Inc.; Penumbra Inc.
Recruiting - verified May 2013 - Condition: Angiosarcoma
Interventions: Drug: Pazopanib; Drug: Pazopanib
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified May 2013 - Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: Nivolumab; Biological: Pazopanib; Drug: Sunitinib; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified May 2013 - Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Interventions: Drug: brentuximab vedotin; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Depression Disorder, Major
Interventions: Drug: RO4995819; Drug: RO4995819; Drug: RO4995819; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Interventions: Drug: 500 mg LX1606 QD; Drug: 500 mg LX1606 TID; Drug: Placebo
Sponsors: Lexicon Pharmaceuticals; Lexicon Pharmaceuticals
Recruiting - verified May 2013 - Condition: Paroxysmal Atrial Fibrillation
Interventions: Device: EAS-AC (HeartLight); Procedure: Control Arm Ablation
Sponsors: CardioFocus; CardioFocus
Recruiting - verified April 2013 - Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Spondylitis, Ankylosing
Interventions: Drug: Golimumab; Drug: Placebo
Sponsors: Merck; Merck; Johnson & Johnson
Recruiting - verified May 2013 - Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions: Drug: Nitric Oxide; Other: Placebo; Drug: Nitric Oxide
Sponsors: INO Therapeutics; INO Therapeutics
Recruiting - verified May 2013 - Condition: Multiple Myeloma
Intervention: Drug: LGH447
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 and Gardasil; Biological: rLP2086; Biological: Gardasil
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2013 - Conditions: Keratoconus; Corneal Ectasia
Interventions: Device: KXL System (15 mW/cm2); Device: KXL System (30 mW/cm2); Device: KXL System (45 mW/cm2); Drug: riboflavin ophthalmic solution
Sponsors: ACOS; ACOS
Recruiting - verified May 2013 - Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013 - Condition: Acute Lymphocytic Leukaemia
Intervention: Drug: SAR3419
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg; Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg; Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo; Drug: GDC-0941; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified May 2013 - Condition: Brain Cancer
Interventions: Drug: Lacosamide; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; BRAIN TUMOR TRIALS COLLABORATIVE (BTTC); UCB, Inc.
Recruiting - verified May 2013 - Condition: Oncology
Intervention: Drug: BAY94-9343
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: Menorrhagia
Interventions: Drug: Oral tranexamic acid; Drug: Oral Contraceptive Pills
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified May 2013 - Condition: Non-24-Hour Sleep-Wake Disorder
Intervention: Drug: tasimelteon
Sponsors: Vanda Pharmaceuticals; Vanda Pharmaceuticals
Recruiting - verified May 2013 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2013 - Conditions: Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin; Drug: rituximab
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Lymphoma
Interventions: Drug: Vorinostat; Drug: Gemcitabine; Drug: Busulfan; Drug: Melphalan; Procedure: Stem Cell Infusion; Drug: Rituximab; Drug: G-CSF; Drug: Palifermin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Ejaculatory Dysfunction; Hypogonadism
Interventions: Drug: Testosterone Solution 2%; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: Prostate Cancer
Interventions: Other: Placebo; Drug: Methylphenidate; Behavioral: Counseling Sessions; Other: Sham Exercise; Other: Standardized Exercise Intervention Program; Other: Cognitive Behavioral Therapy (CBT)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; American Cancer Society, Inc.
Recruiting - verified May 2013 - Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention:
Sponsors: Emory University; Emory University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2013 - Condition: Bipolar 1 Disorder
Interventions: Drug: asenapine; Drug: placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Leukemia
Intervention: Drug: BKM120
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2013 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Cerebral Aneurysm
Interventions: Device: HydroCoil Embolic System; Device: Control (bare platinum coils)
Sponsors: Northwestern University; Northwestern University; MicroVention, Inc
Recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified May 2013 - Condition: Acute Schizophrenia
Interventions: Drug: OPC-34712; Drug: OPC-34712; Drug: OPC-34712; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Condition: Schizophrenia
Intervention: Drug: OPC-34712
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2013 - Condition: Sarcoma, Alveolar Soft Part
Interventions: Drug: Cediranib; Drug: Sunitinib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2013 - Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Temsirolimus; Behavioral: Quality of Life Assessment; Drug: Benadryl
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Primary Biliary Cirrhosis
Interventions: Drug: ustekinumab (double-blind); Drug: ustekinumab (double-blind); Drug: ustekinumab (open-label); Drug: ustekinumab (double-blind); Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013 - Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: AEB071
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Neoplasms
Interventions: Drug: BAY80-6946 + BAY86-9766; Drug: BAY80-6946 + BAY86-9766
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Conditions: Congenital Bleeding Disorder; Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013 - Conditions: Advanced Cancers; Solid Tumors
Interventions: Drug: Panax Ginseng; Dietary Supplement: Placebo; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Indena
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Acute Ischemic Stroke; Diabetes; Hyperglycemia
Interventions: Drug: IV insulin to maintain target glucose concentration of 80-130 mg/dL; Drug: Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
Sponsors: University of Virginia; University of Virginia; Neurological Emergencies Treatment Trials Network (NETT); Medical University of South Carolina; Medical Automation Systems, an Alere Company; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Inotuzumab Ozogamycin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Mesna; Drug: Vincristine; Drug: Dexamethasone; Drug: Pegfilgrastim; Drug: Methotrexate; Drug: Ara-C
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified May 2013 - Condition: Muscular Atrophy
Interventions: Drug: LY2495655; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013 - Conditions: Dystonia; Voice Disorders
Intervention:
Sponsors: Emory University; Hyder A. Jinnah, MD, PhD; National Institute of Neurological Disorders and Stroke (NINDS); Office of Rare Diseases (ORD); Allergan; Dystonia Study Group
Recruiting - verified May 2013 - Condition: Myelofibrosis
Interventions: Drug: GS-6624 at 700 mg; Drug: GS-6624 at 200 mg
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2013 - Condition: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Drug: STX-100; Drug: Placebo
Sponsors: Stromedix, Inc.; Stromedix, Inc.
Recruiting - verified May 2013 - Condition: Congestive Heart Failure
Interventions: Device: HM II® (HeartMate II® LVAD); Other: OMM (Optimal Medical Management)
Sponsors: University of Michigan; University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); Thoratec Corporation
Not yet recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified May 2013 - Conditions: Advanced Solid Tumors,; Selected Solid Tumors
Intervention: Drug: BKM120 + MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Tumor, Solid
Intervention: Drug: MK-8353
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Neoplasms
Interventions: Drug: RO5429083; Drug: RO5429083
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Ovarian Cancer
Interventions: Drug: MK-1775; Drug: Placebo; Drug: paclitaxel; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine; Biological: control
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphomatoid Papulosis; Mycosis Fungoides; Skin Lymphoma; Cutaneous Lymphomas; Lymphoma; Hematologic Disorder
Intervention: Drug: SGN-35
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Seattle Genetics, Inc.
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013 - Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2013 - Conditions: Primary Myelofibrosis; Post Essential Thrombocythemia-myelofibrosis; Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2013 - Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013 - Conditions: SCID; ADA-SCID; XSCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013 - Conditions: Head and Neck Neoplasms; Carcinoma, Squamous Cell
Interventions: Drug: Afatinib; Drug: Methotrexate
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Biological: PF-04236921; Biological: PF-04236921
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Atrophy, Geographic
Interventions: Drug: GSK933776; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2013 - Conditions: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight; Infant, Premature; Bronchopulmonary Dysplasia
Interventions: Drug: Hydrocortisone; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified May 2013 - Conditions: Extra-adrenal Paraganglioma; Metastatic Pheochromocytoma; Paraganglioma; Recurrent Pheochromocytoma
Interventions: Drug: pazopanib hydrochloride; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Multicentric Castleman's Disease
Intervention: Drug: Siltuximab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Conditions: Irritable Bowel Syndrome; Abdominal Pain
Interventions: Other: Low fermentable substrate diet; Other: High fermentable substrate diet
Sponsors: Baylor College of Medicine; Baylor College of Medicine; NASPGHAN Foundation
Recruiting - verified May 2013 - Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Conditions: Chondrosarcoma; Metastatic Chondrosarcoma
Intervention: Drug: pazopanib
Sponsors: ACORN Research, LLC; ACORN Research, LLC; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Lymphoma
Interventions: Drug: Ofatumumab; Drug: Ifosfamide; Drug: Etoposide; Drug: Mesna; Drug: G-CSF; Procedure: Stem Cell Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Breast Neoplasms
Interventions: Drug: Afatinib once daily (OD); Drug: Vinorelbine Weekly
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Dementia; Aggression; Pain
Interventions: Behavioral: PAVeD Intervention; Behavioral: Enhanced Usual Care
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Condition: Solid Tumors
Intervention: Drug: INC280
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hepatitis C
Intervention: Drug: TMC435
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2013 - Condition: Myelofibrosis
Intervention: Drug: Ruxolitinib
Sponsors: Incyte Corporation; Incyte Corporation; Novartis
Recruiting - verified May 2013 - Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013 - Condition: Acute Leukemia
Intervention: Drug: PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
Sponsors: PharmaMar; PharmaMar
Recruiting - verified May 2013 - Conditions: Sepsis; Severe Sepsis; Septic Shock; Multi-organ Failure
Intervention:
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Not yet recruiting - verified May 2013 - Condition: Influenza, Human
Interventions: Drug: Oseltamivir; Drug: Oseltamivir Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified April 2013 - Condition: Breast Cancer
Interventions: Device: Alloderm; Device: Surgimend
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Myeloma
Interventions: Drug: Carfilzomib; Drug: Panobinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis; Onyx Therapeutics, Inc.
Recruiting - verified May 2013 - Conditions: Sexually Transmitted Diseases; Pregnancy; HIV Infections
Interventions: Behavioral: HIV, STI and Pregnancy Prevention Curriculum; Behavioral: Control Curricula
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Alaska Native Tribal Health Consortium; Inter Tribal Council of Arizona; Northwest Portland Area Indian Health Board
Recruiting - verified May 2013 - Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013 - Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Myelodysplasia
Interventions: Biological: human myeloid progenitor cells; Drug: G-CSF
Sponsors: Cellerant Therapeutics; Cellerant Therapeutics; Department of Health and Human Services
Recruiting - verified May 2013 - Condition: Cancer, Solid Tumor
Interventions: Drug: lambrolizumab 1 mg/kg; Drug: lambrolizumab 3 mg/kg; Drug: lambrolizumab 10 mg/kg; Drug: lambrolizumab MEL; Drug: lambrolizumab NSCLC; Drug: lambrolizumab MEL Low Dose; Drug: lambrolizumab MEL High Dose; Drug: lambrolizumab NSCLC Low Dose; Drug: lambrolizumab NSCLC High Dose; Drug: lambrolizumab NSCLC Medium Dose
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Conditions: Solid Tumors; Relapsed/Refractory Sarcomas
Intervention: Drug: Vorinostat and Etoposide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck; Phoenix Children's Hospital; Milton S. Hershey Medical Center; Johns Hopkins University; Sidney Kimmel Comprehensive Cancer Center; Children's Hospital Colorado; University of Florida; Alberta Children's Hospital; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Children's Mercy Hospital & Clinics; All Children's Hospital; Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Genetic: gene expression analysis; Drug: systemic chemotherapy; Drug: tamoxifen citrate; Drug: aromatase inhibition therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Lymphoma, B-Cell
Interventions: Drug: RO5072759; Drug: rituximab [MabThera/Rituxan]; Drug: CHOP chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Fondazione Italiana Linfomi ONLUS
Recruiting - verified May 2013 - Condition: Anemia
Interventions: Drug: LY2787106; Dietary Supplement: Iron Supplementation
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Delayed Graft Function
Intervention: Drug: BB3
Sponsors: Angion Biomedica Corp; Angion Biomedica Corp
Recruiting - verified December 2011 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerConditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Cocaine Dependence
Intervention: Drug: Buspirone
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified May 2013 - Condition: Advanced Cancers
Interventions: Drug: Hydroxychloroquine; Drug: Sirolimus; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Brain Cancer
Interventions: Drug: Vorinostat; Drug: Bevacizumab; Drug: Bevacizumab; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified May 2013 - Condition: Von Hippel-Lindau Syndrome
Intervention: Drug: Dovitinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Welchol for oral suspension placebo proxy; Drug: Welchol for oral suspension
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified May 2013 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Rituximab; Drug: Sapacitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Cyclacel Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention: Biological: Autologous cord blood
Sponsors: The University of Texas Health Science Center, Houston; Charles Cox
Recruiting - verified January 2012 - Condition: Lung Cancer
Interventions: Drug: Erlotinib; Drug: AZD6244; Drug: MK-2206; Drug: Sorafenib; Drug: Erlotinib; Drug: MK-2206
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; AstraZeneca; Bayer; Merck; National Cancer Institute (NCI); OSI Pharmaceuticals; Yale University
Recruiting - verified May 2013 - Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Influenza, Human
Interventions: Drug: 300mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 600mg intravenous (IV) zanamivir and oral oseltamivir placebo; Drug: 75mg oral oseltamivir and intravenous zanamivir placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013 - Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2013 - Condition: Influenza
Interventions: Drug: Amantadine, Ribavirin, Oseltamivir; Drug: Oseltamivir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Advanced Cancer
Intervention: Drug: LY2940680
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Portopulmonary Hypertension
Intervention: Drug: Ambrisentan
Sponsors: Tufts Medical Center; Tufts Medical Center; Gilead Sciences
Recruiting - verified May 2013 - Condition: Head And Neck Cancer
Interventions: Other: Placebo; Drug: Armodafinil; Drug: Minocycline; Drug: Bupropion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Infant Colic; Postpartum Depression
Interventions: Behavioral: The Happiest Baby on The Block; Behavioral: AAP Infant Colic counseling
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2013 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013 - Condition: Advanced Cancers
Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Anal Cancer; Nonneoplastic Condition; Penile Cancer; Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Acute Myocardial Infarction; Pacing Therapy; Cardiac Remodeling; Heart Failure
Interventions: Device: Single Site Pacing; Device: Dual Site Pacing
Sponsors: Medtronic Cardiac Rhythm Disease Management; Medtronic Cardiac Rhythm Disease Management
Recruiting - verified May 2013 - Condition: Lymphoma
Intervention: Biological: DNA Vaccine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Etoricoxib 60 mg; Drug: Etoricoxib 90 mg; Drug: Placebo to Etoricoxib 60 mg; Drug: Placebo to Etoricoxib 90 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013 - Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Glioblastoma Multiforme; GBM; Brain Cancer
Intervention: Biological: Autologous CMV-specific CTL
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital System
Recruiting - verified May 2013 - Condition: Infant, Very Low Birth Weight
Intervention:
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified May 2013 - Conditions: AML; ALL; Blast Crisis; MDS; Multiple Myeloma
Intervention: Drug: TG02 citrate
Sponsors: Tragara Pharmaceuticals, Inc.; Tragara Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Leukemia
Interventions: Drug: 5-azacytidine; Drug: PKC412
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib Standard Dosing Regimen; Drug: Sorafenib Ramp-Up Regimen
Sponsors: University of Florida; University of Florida
Recruiting - verified May 2013 - Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Condition: Skin Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013 - Condition: Gastrointestinal Cancers
Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified May 2013 - Condition: Advanced Cancer
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Sorafenib; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: SCID; Leaky SCID; Omenn Syndrome; Reticular Dysgenesis; ADA Deficiency; XSCID
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases (ORD)
Recruiting - verified May 2013 - Condition: Heart Failure
Intervention: Device: EVAHEART Left Ventricular Assist System (LVAS)
Sponsors: Evaheart Medical USA, Inc.; Evaheart Medical USA, Inc.
Recruiting - verified May 2013 - Condition: Ischemic Stroke
Intervention: Drug: Alteplase (iv t-PA)
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Genentech
Recruiting - verified May 2013 - Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Condition: Hodgkin's Lymphoma
Interventions: Drug: Panobinostat; Drug: Ifosfamide; Drug: Mesna; Drug: Carboplatin; Drug: Etoposide; Drug: Pegfilgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2013 - Conditions: CLL; Leukemia
Intervention: Drug: Eltrombopag
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention: Other: Blood/saliva sampling
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified May 2013 - Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Aliskiren; Drug: Aliskiren
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013 - Conditions: Head and Neck Cancer; Long-term Effects Secondary to Cancer Therapy in Adults; Oral Complications of Chemotherapy and Head/Neck Radiation; Radiation Toxicity; Xerostomia
Intervention: Procedure: Acupuncture
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Spinal Cord Injuries
Intervention: Behavioral: Vocational Rehabilitation
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013 - Conditions: Attention Deficit Hyperactivity Disorder; Reading Disabilities
Interventions: Drug: Methylphenidate; Behavioral: Intensive reading instruction; Behavioral: Parent Training; Drug: Mixed Salt Amphetamine; Drug: Atomoxetine; Drug: Guanfacine
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Children's Hospital Medical Center, Cincinnati
Recruiting - verified May 2013 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
Interventions: Drug: decitabine; Drug: vorinostat; Drug: cytarabine; Other: pharmacological study; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: Ribavirin; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207217; Drug: BI 201335; Drug: BI 207127; Drug: Ribavirin; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013 - Conditions: Advanced Cancer; Squamous Cell Carcinoma; Carcinoma, Squamous Cell of Head and Neck; Lung Squamous Cell Carcinoma Stage IV; Anal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung
Intervention: Drug: LY2606368
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2013 - Condition: Stroke, Acute
Interventions: Device: hypothermia; Other: Group1: IV t-PA and normothermia
Sponsors: University of California, San Diego; University of California, San Diego; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013 - Condition: Glioblastoma Multiforme (GBM)
Intervention: Genetic: Genetically modified HER.CAR CMV-specific CTLs
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified May 2013 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified May 2013 - Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: plitidepsin + dexamethasone; Drug: dexamethasone
Sponsors: PharmaMar; PharmaMar
Recruiting - verified March 2013 - Condition: Chronic Obstructive Pulmonary Disease
Intervention:
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified May 2013 - Condition: Advanced Cancer
Interventions: Drug: Sirolimus; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Bladder Cancer
Intervention: Device: Neo-Urinary Conduit
Sponsors: Tengion; Tengion
Recruiting - verified April 2013 - Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2013 - Condition: Intraabdominal Infections
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsors: Bayer; Bayer
Recruiting - verified April 2013 - Conditions: Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma
Interventions: Drug: pemetrexed disodium; Drug: cisplatin; Drug: cediranib maleate; Other: placebo
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Brain Tumor; Medulloblastoma; Pineoblastoma
Intervention: Radiation: proton beam radiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Influenza
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified May 2013 - Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone; Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013 - Condition: Influenza A
Interventions: Biological: Anti-Influenza Plasma; Behavioral: Standard Care
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified May 2013 - Condition: Gynecologic Cancer
Intervention: Behavioral: Surveys
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Conditions: Thymoma; Thymic Carcinoma.; Clinical Masaoka Stage II-IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Condition: Bronchopulmonary Dysplasia
Intervention: Drug: Infasurf surfactant (ONY, Inc.)
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Condition: Neuroblastoma
Interventions: Drug: Vorinostat; Radiation: 131- I Metaiodobenzylguanidine; Procedure: Peripheral Blood Stem Cell Infusion; Drug: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Advanced Cancer
Interventions: Drug: Dasatinib; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Condition: Factor X Deficiency
Intervention: Biological: FACTOR X
Sponsors: Bio Products Laboratory; Bio Products Laboratory
Recruiting - verified May 2013 - Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Interventions: Behavioral: Exercise Program; Behavioral: Telephone-based intervention; Other: Counseling intervention; Other: Questionnaire administration; Behavioral: Relaxation Program
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Sepsis Induced ALI
Interventions: Drug: Rosuvastatin; Drug: Placebo
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2013 - Conditions: Leukemia; Acute Lymphocytic Leukemia
Interventions: Drug: Everolimus (RAD001); Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Mesna; Drug: Methotrexate; Drug: Ara-C (Cytarabine); Drug: Methylprednisone; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2013 - Condition: Breast Cancer
Intervention: Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2013 - Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Docetaxel; Drug: Carboplatin; Drug: Dexamethasone; Biological: EBV-specific cytotoxic T lymphocytes
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Condition: Brain Disease
Interventions: Procedure: Stereotactic Radiosurgery (SRS); Procedure: MRI
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Advanced Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Leukemia
Interventions: Drug: Vorinostat; Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified May 2013 - Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Smoking Cessation; Habits; Smoking
Interventions: Behavioral: Survey; Behavioral: Counseling; Behavioral: Survey; Behavioral: Counseling
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Advanced Cancers
Interventions: Drug: HAI Oxaliplatin; Drug: 5-FU; Drug: Bevacizumab; Drug: Cetuximab; Drug: Leucovorin; Drug: 5-FU; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Advanced Cancer
Interventions: Drug: Sirolimus; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine; Drug: 5-Azacytidine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Radiation: Radiation Therapy; Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Traumatic Spinal Cord Injury; Neuropathic Pain
Intervention: Other: blood samples
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; The Institute of Rehabilitation and Research (TIRR)
Recruiting - verified May 2013 - Conditions: Need for MRI Imaging With Pacemaker or; Implantable Cardioverter Defibrillator Implanted
Intervention: Device: MRI with pacemaker or ICD
Sponsors: Scripps Health; Scripps Health; The Scripps Foundation; The Hewitt Medical Research Foundation; St. Jude Medical; Boston Scientific Corporation; Biotronik, Inc.
Recruiting - verified August 2012 - Condition: Sarcoma
Intervention: Genetic: Autologous HER2-specific T cells
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2013 - Condition: Myelodysplastic Syndrome
Interventions: Drug: Decitabine; Drug: Clofarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genzyme
Recruiting - verified May 2013 - Conditions: Graft Rejection; Kidney Transplant; Renal Allograft Recipients; Renal Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Tacrolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Condition: HER2 Positive Malignancies
Intervention: Genetic: TGFBeta resistant HER2/EBV-CTLs
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified May 2013 - Conditions: Leukemia; AML; MDS
Intervention: Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Cytomegalovirus Infection; Adenovirus Infection
Intervention: Biological: Dose Escalation Comparison
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2013 - Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2013 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified May 2013 - Conditions: Colorectal Cancer; Lung Cancer; Liver Cancer
Intervention: Procedure: PET/CT Scan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GE Healthcare
Recruiting - verified May 2013 - Condition: Neurological Conditions
Intervention: Other: tissue and data repository
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; The Vivian L. Smith Center for Neurologic Research
Recruiting - verified May 2013 - Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Invasive Aspergillosis
Intervention: Drug: Voriconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Prostate Cancer
Intervention: Drug: TK1258
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2013 - Condition: Solid Tumors
Intervention: Drug: axitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Traumatic Brain Injury
Intervention: Drug: Progesterone
Sponsors: Emory University; David Wright
Recruiting - verified May 2013 - Condition: Heart Failure
Intervention: Device: CentriMag Ventricular Assist System
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013 - Condition: Candidiasis
Interventions: Drug: micafungin; Drug: amphotericin B deoxycholate
Sponsors: Astellas Pharma Inc; Astellas Pharma Global Development, Inc.
Recruiting - verified April 2013 - Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)Conditions: Stem Cell Transplantation; Leukemia
Interventions: Drug: Fludarabine; Drug: Busulfan; Drug: Thymoglobulin; Drug: Azacitidine; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Cervical Cancer
Intervention: Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Peyronie's Disease
Interventions: Drug: 100 units of BOTOX®; Other: Preservative free normal saline
Sponsors: Baylor College of Medicine; Mohit Khera; Allergan
Recruiting - verified May 2013 - Condition: Acute Myelogenous Leukemia
Interventions: Drug: Fludarabine; Drug: Cytarabine; Drug: G-CSF (Filgrastim, Neupogen); Drug: Idarubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Hyperplasia; Endometrial Cancer
Intervention: Device: Levonorgestrel IUD
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2013 - Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013 - Conditions: Acute Myocardial Infarction (AMI); Coronary Occlusion; Acute Coronary Syndrome
Intervention: Device: AngelMed Guardian System
Sponsors: Angel Medical Systems; Angel Medical Systems; Symbios Clinical
Recruiting - verified May 2013 - Condition: Colorectal Cancer
Intervention: Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Pancreatic Cancer; Pancreatic Adenocarcinoma
Interventions: Drug: MK-0646; Drug: Gemcitabine; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified April 2013 - Condition: Head and Neck Cancer
Interventions: Behavioral: Interview; Behavioral: Phone Call; Other: Brochure; Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Cholestasis; Parenteral Nutrition
Intervention: Drug: Omegaven
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Children's Hospital Boston
Recruiting - verified May 2013 - Conditions: Paranasal Sinus Neoplasms; Squamous Cell Carcinoma
Interventions: Drug: Docetaxel; Drug: 5-Fluorouracil; Drug: Cisplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sanofi
Recruiting - verified April 2013 - Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Procedure: colposcopic biopsy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Smoking
Interventions: Behavioral: Focus Group; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Procedure: Digital Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Gynecologic Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified April 2013 - Conditions: Multiple Myeloma; Primary Amyloidosis
Interventions: Drug: Melphalan; Procedure: Stem Cell Infusion; Behavioral: Questionnaires; Drug: Granulocyte-colony stimulating factor (G-CSF); Procedure: Apheresis
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Rectal Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Brain Disorders
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified August 2012 - Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified April 2013 - Condition: Colorectal Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Hernia
Intervention:
Sponsors: Ethicon, Inc.; Ethicon, Inc.
Recruiting - verified April 2013 - Condition: Graft Versus Host Disease
Interventions: Procedure: Photopheresis; Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Rhabdomyosarcoma
Intervention: Radiation: Proton Beam Radiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; M.D. Anderson Cancer Center; Brigham and Women's Hospital; Children's Hospital Boston; Dana-Farber Cancer Institute; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: B Cell Lymphoma; Chronic Lymphocytic Leukemia
Interventions: Genetic: CD19CAR-zeta and CD19CAR-28-zeta T cells; Drug: Ipilimumab
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified May 2013 - Condition: Influenza
Interventions: Drug: oseltamivir; Drug: oseltamivir; Other: Alternative Control
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013 - Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Advanced Cancer; Pain
Intervention: Other: Sensory Tests
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Hereditary Nonpolyposis Colorectal Cancer; Lynch Syndrome
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Melanoma
Interventions: Procedure: Blood Sample; Procedure: Tumor Sample
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Advanced Cancer
Interventions: Behavioral: Questionnaire; Device: Actigraph
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Leukemia
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); Mayo Clinic
Recruiting - verified May 2013 - Conditions: Leukemia; Lymphoblastic Lymphoma; Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Vincristine; Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Endometrial Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Chondrosarcoma
Intervention: Procedure: Proton Beam Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Laparoscopy
Intervention: Other: Laparoscopic Surgery Data Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013 - Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2013 - Condition: Crohn's Disease
Interventions: Drug: adult human mesenchymal stem cells; Drug: Placebo
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2013 - Condition: Prostate Cancer
Intervention: Procedure: 3T Magnetic Resonance Spectroscopic Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified April 2013 - Condition: Epilepsies, Partial
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013 - Conditions: Cocaine Abuse; Cocaine Dependence; Opiate Dependence; Alcohol Dependence; Substance Abuse
Interventions: Drug: modafinil; Drug: d-amphetamine; Drug: L-Dopa; Drug: Naltrexone
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; National Institute on Drug Abuse (NIDA)
Recruiting - verified December 2009 - Condition: Retinoblastoma
Interventions: Radiation: Proton Beam Radiation Therapy; Procedure: Ophthalmic EUA
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2013 - Conditions: Recurrent Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: entinostat; Drug: azacitidine; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Hodgkin's Disease
Interventions: Drug: Gemcitabine; Drug: Fludarabine; Drug: Melphalan; Drug: Antithymocyte Globulin; Procedure: Allogeneic Stem Cell Infusion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2013 - Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified May 2013 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Retinitis Pigmentosa; Inherited Ophthalmic Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified May 2012 - Conditions: Systemic Sclerosis; Scleroderma; Pulmonary Hypertension; Pulmonary Arterial Hypertension
Intervention:
Sponsors: Georgetown University; Georgetown University; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Corneal Dystrophies, Hereditary; Corneal Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified July 2012 - Condition: Colon Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2013 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013 - Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Bosentan; Drug: Sildenafil Citrate
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013 - Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin; Drug: inotuzumab ozogamicin
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013 - Conditions: Smoking; Tobacco Use Cessation
Interventions: Behavioral: MBAT Group Therapy; Drug: Nicotine; Behavioral: Group Therapy; Behavioral: Individual Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2013 - Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: T Cells; Biological: Interleukin-2; Drug: Mesna
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Chiron Corporation
Recruiting - verified May 2013 - Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013 - Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013 - Conditions: Brain Injuries, Traumatic; Traumatic Brain Injury
Intervention: Other: Blood/saliva samples for protein/molecular analysis
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; TIRR/Mission Connect; The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston
Recruiting - verified May 2013 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified May 2013 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2013 - Condition: Epstein-Barr Virus Infections
Intervention: Biological: EBV specific T cells
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2013 - Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2013

Clinical Trial Locations 